Journal of Clinical and Preventive Cardiology

BRIEF COMMUNICATION
Year
: 2017  |  Volume : 6  |  Issue : 2  |  Page : 68--69

Dexrazoxane in anthracycline cardiotoxicity


Abhijit S Nair 
 Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad, Telangana, India

Correspondence Address:
Abhijit S Nair
Department of Anaesthesia and Pain Medicine, Basavatarakam Indo American Cancer Hospital and Research Centre, Hyderabad - 500 034, Telangana
India

Anthracycline group of antineoplastic agents is notorious for causing cumulative dose induced cardiotoxicity which is more pronounced in elderly patients and in patients with preexisting cardiac comorbidities. Several preventive strategies have been explored with variable success and without randomized studies and insufficient data. Dexrazoxane is an ethylenediaminetetraacetic acid analog which has been found to be effective when used before or along with anthracycline infusion. The drug is also found to be useful in counteracting injuries caused due to anthracycline extravasation in the tissues.


How to cite this article:
Nair AS. Dexrazoxane in anthracycline cardiotoxicity.J Clin Prev Cardiol 2017;6:68-69


How to cite this URL:
Nair AS. Dexrazoxane in anthracycline cardiotoxicity. J Clin Prev Cardiol [serial online] 2017 [cited 2022 May 26 ];6:68-69
Available from: https://www.jcpconline.org/article.asp?issn=2250-3528;year=2017;volume=6;issue=2;spage=68;epage=69;aulast=Nair;type=0